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ABSTRACT
Background. Ferumoxytol was first approved for clinical use in
2009 solely based on data from trial comparisons with oral iron
on biochemical anemia efficacy end points. To compare the
rates of important patient outcomes (infection, cardiovascular
events and death) between facilities predominantly using feru-
moxytol versus iron sucrose (IS) or ferric gluconate (FG) in
patients with end-stage renal disease (ESRD)-initiating hemo-
dialysis (HD).
Methods.Using the United States Renal Data System, we iden-
tified all HD facilities that switched (almost) all patients from
IS/FG to ferumoxytol (July 2009–December 2011). Each
switching facility was matched with three facilities that contin-
ued IS/FG use. All incident ESRD patients subsequently initi-
ating HD in these centers were studied and assigned their
facility exposure. They were followed for all-cause mortality,
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cardiovascular hospitalization/death or infectious hospitaliza-
tion/death. Follow-up ended at kidney transplantation, switch
to peritoneal dialysis, transfer to another facility, facility switch
to another iron formulation and end of database (31 December
2011). Cox proportional hazards regression was then used to
estimate adjusted hazard ratios [HR (95% confidence
intervals)].
Results. In July 2009–December 2011, 278 HD centers
switched to ferumoxytol; 265 units (95.3%) were matched
with 3 units each that continued to use IS/FG. Subsequently,
14 206 patients initiated HD, 3752 (26.4%) in ferumoxytol
and 10 454 (73.6%) in IS/FG centers; their characteristics
were very similar. During 6433 person-years, 1929 all-cause,
726 cardiovascular and 191 infectious deaths occurred. Patients
in ferumoxytol (versus IS/FG) facilities experienced similar all-
cause [0.95 (0.85–1.07)], cardiovascular [0.99 (0.83–1.19)] and
infectious mortality [0.88 (0.61–1.25)]. Among 5513 Medicare
(Parts A + B) beneficiaries, cardiovascular events [myocardial
infarction, stroke and cardiovascular death; 1.05 (0.79–1.39)]
and infectious events [hospitalization/death; 0.96 (0.85–1.08)]
did not differ between the iron exposure groups.
Conclusions. In incident HD patients, ferumoxytol showed
similar short- to mid-term safety profiles with regard to car-
diovascular, infectious and mortality outcomes compared
with the more commonly used intravenous iron formulations
IS and FG.
Keywords: cardiovascular, infection, intravenous iron, mortal-
ity, safety
INTRODUCTION
Ferumoxytol was introduced as an alternative intravenous iron
formulation and was approved ‘for the treatment of iron defi-
ciency anemia in adult patients with chronic kidney disease’
(CKD) by the US Food and Drug Administration (FDA) on
30 June 2009 [1]. The three registrational trials supporting
the approval were limited in scope and size, essentially compar-
ing the efficacy of ferumoxytol with oral iron fumarate on the
end point of hemoglobin concentration (as was customary for
FDA approval of anemia drugs) in patients with nondialysis
CKD (two trials) or dialysis-requiring CKD (one trial) [1–3].
Over 35 days of follow-up, ferumoxytol was superior compared
with oral iron in all three trials in the efficacy end point of
change from baseline hemoglobin concentration and appeared
generally safe in these trials as well as another (crossover) trial of
713 patients [1, 4]. However, no head-to-head comparisons
with other available intravenous iron products were required
and quality data on the longer term safety remain limited [4–6].
Ferumoxytol differed from the other intravenous iron for-
mulations available at the time in that a larger iron dose of
510 mg could be administered in a single, short injection. In
contrast, previously available iron formulations required re-
peated injections or infusions of smaller iron doses. While
this clinical advantage of ferumoxytol is particularly appealing
for its use in patients with CKD not requiring dialysis or those
undergoing peritoneal dialysis, its use has also been adopted by
several US hemodialysis providers [6]. However, studies com-
paring the safety of ferumoxytol versus other intravenous iron
formulations are limited.
Intravenous iron preparations differ in the way they envelop
the iron core and there are likely differences in the amount of
free iron that may get released into the blood stream (‘labile
iron’) [7]. Free iron may put patients at acute risk of anaphyl-
actic reactions and—in the longer term—exert clinically im-
portant toxicity with particular concerns about cardiovascular
or infectious risks [7].
We conducted the present study to examine the safety of fer-
umoxytol use compared with other available intravenous iron
products in real life practice. We applied an innovative study de-
sign that exploits the natural experiment, which occurs when in-
dividual dialysis facilities make formulary decisions and provide a
single intravenous iron product to all or almost all of their patients.
MATERIALS AND METHODS
Study rationale
Most dialysis facilities restrict the choice among available
intravenous iron formulations to a single one, which is then
used for most or all of its patients. For the purpose of this
study, we considered the choice among ferumoxytol, iron sucrose
(IS) and sodium ferric gluconate (FG) as potentially randomwith
regard to patient characteristics because such decisions, particu-
larly at the introduction of a new drug, are often based on con-
tracts with drug suppliers. Since it is not expected that patients
choose a facility based on whether it uses one intravenous iron
formulation or another, we have the opportunity to exploit
these facility-level decisions as a natural experiment. Specifically,
we used administrative data to mimic a cluster-randomized de-
sign, with clustering based on facility by assigning facilities and
their incident hemodialysis patients to a treatment arm based on
the predominant practice pattern of their facility. We have re-
cently applied this design in a comparative safety study among
erythropoiesis-stimulating agents [8].
Study population—patient selection, exposure
assignment and follow-up
From the United States Renal Data System (USRDS), the na-
tional registry of persons with end-stage renal disease (ESRD),
we identified all intravenous iron administrations from billing
codes to Medicare between 1 January 2009 and 31 December
2011. We then defined for each hemodialysis facility and calen-
dar month the proportion of intravenous administrations that
were for ferumoxytol versus IS versus FG. For each facility, we
termed a calendar month a ferumoxytol facility-month if≥90%
of administered intravenous iron administrations in that facility
and month were ferumoxytol; correspondingly, if ≥90% of ad-
ministrations were IS (or FG), we considered it an IS (or FG)
facility-month. All other facility-months were categorized as
‘mixed’. Beginning with the approval of ferumoxytol by the
US FDA for the US market on 30 June 2009, we identified all
facility-level switches from IS (or FG) to ferumoxytol.
We conducted all analyses using two approaches. One ap-
proach considered non-ferumoxytol facilities predominantly
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using IS as well as facilities predominantly using FG as matching
candidates. This approach yielded better opportunities to match
ferumoxytol facilities and enabled us to use a higher matching
ratio (1:3). However, this approach assumes that IS and FG are
equally safe with regard to the outcomes studied. Some studies
have challenged this class assumption between IS and FG and
so we repeated our analyses only considering IS facilities; for
these analyses, we used a matching ratio of 1:2. (Corresponding
analyses between ferumoxytol and FG facilities were not con-
ducted due to the relative paucity of FG facilities and our subse-
quent inability to match most ferumoxytol facilities.) Facilities
were matched on the index month, geographic region (Census
Division), chain (versus non-chain) affiliation and facility type
(free standing versus hospital based) as reported in the USRDS.
From the first day of the matching month onward, we iden-
tified all patients regardless of their insurance status who in-
itiated hemodialysis in a ferumoxytol facility and its matched
IS (or FG) facility. If a facility switched back from predominant
ferumoxytol to predominant IS (or FG) use, all matched facil-
ities in the set were no longer eligible to contribute new incident
patients to the study and all existing patients in thematching set
were censored for further follow-up. Conversely, if a matching
IS (or FG) facility switched to ferumoxytol, the matching set of
the ferumoxytol facility and the remaining IS (or FG) facility
continued to contribute patients and person time until all re-
maining IS (or FG) facilities switched upon which all patients
arising from this matching set were censored. Since iron ther-
apy is usually intermittent, depending on iron status measure-
ments, dosing approach (bolus versus maintenance) and
potential temporary contraindications (e.g. infections), patients
may have received continuous, intermittent or no iron treat-
ment, but most always with the intravenous iron formulation
identified as predominantly used by their facility at the time.
We used the ensuing cohort to study mortality outcomes,
which are recorded in the USRDS regardless of payer. Patients
were censored at the end of available data (31 December 2011),
upon switching to peritoneal dialysis, upon receipt of a kidney
transplant, when switching to another hemodialysis facility, or
when their facility or its match switched to predominant use of
another intravenous iron formulation as described in detail above.
For analyses on nonfatal outcomes, we relied on claims-based
data. Therefore, we restricted the cohort to patients who survived
90 days after the start of dialysis and who had Medicare Parts
A + B as their primary payer on that day. In the USA, most pa-
tients with ESRD are eligible for Medicare benefits after a 90-day
waiting period from the date of ESRD incidence certified in the
Medical Evidence Report (form CMS-2728). Patients were fol-
lowed from Day 91 after initiation of hemodialysis until censor-
ing for the reasons listed above, as well as death (for nonfatal
outcomes), or loss of Medicare Parts A + B coverage.
To examine the validity of using facility preference as the
proxy for true exposure over time, as well as to illustrate other
key anemia practice parameters, we plotted for each month of
follow-up the mean dose of intravenous iron formulations re-
ceived, the mean dose of erythropoiesis-stimulating agents
received and the mean hemoglobin concentration achieved
for each exposure group among incident patients who had
Medicare Parts A + B.
Patient characteristics
From the USRDS patient file, we ascertained patients’ age,
sex, race (White, Black, Asian, Native American/Pacific Island-
er and other), ethnicity (Hispanic versus non-Hispanic) and
whether they were covered by Medicaid (a means-tested federal
program administered on the state level, which serves as a proxy
for low-socioeconomic status). From the Medical Evidence Re-
port, we ascertained the reported presence of several comorbid-
ities (diabetes, hypertension, arteriosclerotic heart disease,
heart failure, peripheral artery disease, cerebrovascular disease,
chronic obstructive lung disease, cancer, inability to ambulate
or transfer, tobacco use, drug use and alcohol use) as well as
body mass index, serum hemoglobin and serum albumin con-
centrations and the reported estimated glomerular filtration
rate at initiation of dialysis.
Outcomes
Mortality from any cause, cardiovascular mortality and
mortality from an infectious cause were ascertained from the
death file in the USRDS, which collates pertinent information
from several sources. Nonfatal outcomes of interest
were ascertained from International Classification of Diseases
(9th Revision; ICD-9) diagnosis codes from inpatient Medicare
claims using validated algorithms and included stroke (ICD-9:
430, 431, 432.x, 433.x1, 434.x1, 436, 437.1), myocardial infarc-
tion (MI; ICD-9: 410.x1), as well as a composite of stroke, MI
and cardiovascularmortality. In addition, we investigated infec-
tious outcomes using a composite of infectious hospitalization
and death reportedly due to an infectious cause [9].
Table 1. Characteristics of ferumoxytol and matched IS or sodium FG
complex facilities
Variable Ferumoxytol IS or sodium
FG complex
n = 265 % n = 795 %
Facility typea
Non-chain 152 57.4 456 57.4
Chain 113 42.6 339 42.6
Facility typea
Free standing 254 95.8 762 95.8
Hospital based 11 4.2 33 4.2
Profit status
Missing 2 0.3
Not for profit 64 24.2 130 16.4
For profit 201 75.8 663 83.4
Facility size
0–49 96 36.2 289 36.4
50+ 169 63.8 506 63.6
Regiona
Northwest 49 18.5 147 18.5
Midwest 57 21.5 171 21.5
South 93 35.1 279 35.1
West 66 24.9 198 24.9
aFrom among 278 facilities that switched from IS or sodium FG complex to ferumoxytol
between July 2009 and December 2011, we hard-matched three dialysis units each that
remained with IS or sodium FG complex on facility type (hospital based versus free
standing), chain (versus non-chain) affiliation and geographic region in the month and
year of the switching event. Wewere able to match 265 (95.3%) of facilities that switched to
ferumoxytol.
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Statistical analysis
We first tabulated the characteristics of the matched feru-
moxytol and IS (or FG) facilities. We then tabulated the char-
acteristics of all enrolled incident hemodialysis patients by
whether they dialyzed in a ferumoxytol versus an IS (or FG) fa-
cility. Groups were compared using standardized differences
with <10%, indicating good balance [10]. We examined cumu-
lative incidence plots for all outcomes for any differences in event
rates or censoring events. We used Cox proportional hazards
regression stratified on matching set to estimate unadjusted haz-
ard ratios (HR) and corresponding 95% confidence intervals
(95% CI). Schoenfeld residual plots were examined to identify
any violations of the proportionality assumption. Since a few
characteristics were slightly unbalanced between groups, we
also fit demographics-adjusted models andmodels that included
all reported comorbidities and biometric/laboratory characteris-
tics. Missing data were addressed with multiple imputation by
chained equation using the MICE package in R [11].
We conducted statistical analyses using SAS software,
version 9.3 (www.sas.com) and R (www.r-projects.org). The
Stanford University School of Medicine and Baylor College of
Medicine Institutional Review Boards approved the study.
RESULTS
Between July 2009 and December 2011, 278 US small-chain or
independent hemodialysis facilities adopted predominant use
of ferumoxytol for their patients, of which we matched on facil-
ity type, chain status and geographic region 265 units (95.3%)
with 3 units each that had continued to predominantly use IS or
FG in the samemonth and year. Their facility characteristics are
shown in Table 1. After the index date and prior to censoring of
the matched facility pair, 14 206 patients initiated hemodialysis
in these centers, 3752 (26.4%) in ferumoxytol and 10 454
(73.6%) in IS or FG facilities. Patient characteristics were
quite similar among patients initiating hemodialysis in feru-
moxytol versus IS or FG facilities (Table 2); all measured char-
acteristics had a standardized difference of <10, indicating good
balance. Patient-level separation of iron exposure during
follow-up, assessed from monthly prevalent patients with
Medicare coverage in these units, was excellent: 89.3% of pa-
tients received only IS/FG in this exposure group (1.8% received
only ferumoxytol and 8.8% received both IS/FG and ferumox-
ytol), whereas 83.9% of patients received only ferumoxytol in
Table 2. Characteristics of patients initiating dialysis in matched ferumoxytol and IS or sodium FG complex facilities
Variable (% missing) All patients Ferumoxytol IS or sodium FG complex SD
n or median,
14 206
% or IQR n or mean,
3752
% or IQR n or mean,
10 454
% or IQR
Age (years) 65 55–76 65 54–75 66 55–76 −2.9
Female sex 6220 43.8 1658 44.2 4562 43.6 −1.1
Race (0.2%)
White 9457 66.6 2620 69.8 6837 65.4 1.7
Black 3612 25.4 858 22.9 2754 26.3 −7.8
Asian 959 6.8 239 6.4 720 6.9 −2.1
Other 138 1.0 26 0.7 112 1.1 −4.0
Hispanic ethnicity (0.7%) 2311 16.3 703 18.7 1608 15.4 8.9
Medicaid eligibility 4161 29.3 1087 29.0 3074 29.4 −1.0
Comorbidities
Diabetes 8006 56.4 2109 56.2 5897 56.4 −0.5
Hypertension 12 307 86.6 3275 87.3 9032 86.4 2.6
Arteriosclerotic heart disease 3429 24.1 987 26.3 2442 23.4 6.8
Heart failure 4848 34.1 1387 37.0 3461 33.1 8.1
Peripheral vascular disease 2017 14.2 620 16.5 1397 13.4 8.9
Cerebrovascular disease 1465 10.3 431 11.5 1034 9.9 5.2
Chronic obstructive lung disease 1544 10.9 404 10.8 1140 10.9 −0.5
Cancer 1206 8.5 310 8.3 896 8.6 −1.1
Unable to ambulate 1305 9.2 367 9.8 938 9.0 2.8
Unable to transfer 694 4.9 173 4.6 521 5.0 −1.8
Tobacco use 897 6.3 244 6.5 653 6.2 1.0
Drug use 213 1.5 68 1.8 145 1.4 3.4
Alcohol use 274 1.9 85 2.3 189 1.8 3.2
Reported measurements
Body mass index, kg/m2 (2.2%) 27.7 23.7–33.0 27.8 23.7–33.3 27.7 23.6–32.9 3.6
<18.5 510 3.6 142 3.8 368 3.5 1.5
18.5–24.9 4171 29.4 1078 28.7 3093 29.6 −1.8
25.0–29.9 3956 27.8 1032 27.5 2924 28.0 −0.9
≥30.0 5268 37.1 1415 37.7 3853 36.9 2.0
Hemoglobin, g/dL (7.3%) 9.7 8.8–10.7 9.7 8.8–10.6 9.7 8.8–10.7 −0.2
Serum albumin, g/dL (22.2%) 3.2 2.7–3.6 3.2 2.7–3.6 3.2 2.7–3.6 −1.9
eGFR at time of dialysis initiation,mL/min per 1.73
m2 (3.0%)
10.4 7.6–14.0 10.6 7.8–14.2 10.4 7.5–13.9 5.3
All incident hemodialysis patients in these facilities were captured for analysis of mortality end points regardless of their health insurance status. eGFR, estimated glomerular filtration rate;
ESRD, end-stage renal disease; IQR, interquartile range; SD, standardized difference.
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this corresponding exposure group (6.9% received only IS/FG
and 9.2% received both IS/FG and ferumoxytol). Mean dose
of administered intravenous iron was marginally lower in the
ferumoxytol group and the mean erythropoiesis-stimulating
agent dose administered was comparable and the mean hemo-
globin concentration that patients achieved during follow-up
was essentially identical between the two exposure groups
(Figure 1), thus validating that other anemia practices were
not meaningfully different between ferumoxytol facilities and
those predominantly using IS or FG.
During follow-up over a total of 6433 person-years, 1929
deaths, 726 cardiovascular deaths and 191 infectious deaths oc-
curred for incidence rates of 300, 113 and 30 per 1000 person-
years, respectively (Table 3). Compared with patients who in-
itiated dialysis in IS or FG facilities, patients in ferumoxytol
facilities experienced similar all-cause mortality (HR: 0.95;
95% CI: 0.85–1.07), cardiovascular mortality (HR: 0.99; 95%
CI: 0.83–1.19) and mortality from infectious causes (HR:
0.88; 95% CI: 0.61–1.25). These results were robust to adjust-
ment for demographic or clinical characteristics (Table 3).
For analyses of nonfatal end points that were ascertained
from medical claims, we identified 5513 incident hemodialysis
patients who were alive and covered by Medicare Parts A + B at
90 days after the reported ESRD date: 1545 (28.0%) in ferumox-
ytol and 3968 (72.0%) in IS or FG facilities. There were fewer
Black and more Hispanic individuals in ferumoxytol facilities;
all other characteristics were once again balanced with standar-
dized differences <10 (Table 4). Over 1848 person-years, 297
cardiovascular events (MIs, strokes and cardiovascular deaths)
occurred for an incidence rate of 161 per 1000 person-years,
with no difference between the iron exposure groups
(HR: 1.05; 95% CI: 0.79–1.39; Table 3). Infectious hospitaliza-
tions occurred in 1792 individuals for an incidence rate of 1266
per 1000 person-years, also not different between patients
treated in ferumoxytol versus in IS or FG facilities (HR: 0.96;
95% CI: 0.85–1.08; Table 3). These results were insensitive to
adjustment for any recorded baseline characteristics.
In sensitivity analyses that restricted the comparison group
to facilities predominantly using IS, we matched all 278 feru-
moxytol with 556 IS facilities (Supplementary Table S1). Mor-
tality analyses were conducted in 12 881 incident patients and
outcomes that included nonfatal events were evaluated in 4940
incident patients who survived to Day 90 from their ESRD
incidence date. In these analyses, there were fewer Blacks and
moreHispanics in ferumoxytol facilities. In addition, certain car-
diovascular comorbidities were more common among patients
in ferumoxytol facilities (Supplementary Tables S2 and S3),
while all other characteristics were balanced. Similar to the
main analyses, outcomes were generally similar between
patients initiating dialysis in a ferumoxytol versus an IS facility
(Supplementary Table S4) whether adjusted or not.
DISCUSSION
We used the national US ESRD registry to compare the out-
comes of hemodialysis patients treated at facilities using feru-
moxytol with other patients treated at facilities that almost
exclusively used either IS or FG. Using the observed preference
of predominantly using one specific iron product as an instru-
ment, we observed no difference between ferumoxytol and the
other commonly used intravenous iron formulations with
regard to mortality, cardiovascular or infectious outcomes.
Contract negotiations for the, often exclusive, addition of a
specific drug to the provider’s formulary recur repeatedly lead-
ing entire facilities to switch all of their patients to another
product if the new contract is with another manufacturer. As
a result, most US facilities used either sodium FG complex
(approved by the FDA on 18 February 1999) or IS (approved
by the FDA on 6November 2000) for almost all of their patients
for more than a decade. (Iron dextrans had essentially been
abandoned due to their risk of rare, but severe side effects.)
On 30 June 2009, ferumoxytol was approved by the FDA as
F IGURE 1 : Comparison of anemia treatment characteristics during
follow-up between patients initiating dialysis in ferumoxytol and
matched IS or sodium FG complex facilities (IS/FG; patients on
Medicare A and B in the corresponding month). (A) Mean monthly
intravenous iron dose (in mg). (B) Mean monthly erythropoiesis-
stimulating agent dose (in units). (C) Mean achieved hemoglobin
concentration (in g/dL).
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an additional choice for intravenous iron therapy in ESRD.
Since these negotiations do not consider the types of patients
cared for and—conversely—patients do not select dialysis facil-
ities for the specific iron formulation they use, this ‘natural ex-
periment’ provides a suitable instrument to comparative
effectiveness questions, especially for medications that may
not be given continuously.
Head-to-head comparisons of intravenous iron formula-
tions are rare and the assumption of a treatment class regarding
similar effectiveness and safety appears commonly accepted.
Table 3. Follow-up time, number of events, incidence rates and HR; incident patients in hemodialysis centers using ferumoxytol versus IS or sodium FG
complex
Outcome Sample
size
Follow-up time
(person-years)
Number of
events
Incidence rate
(per 1000
person-years)
Unadjusted HR
(95% CI)
Model 1, HR*
(95% CI)
Model 2,
HR** (95%CI)
Mortality 14 206 6432.7 1929 299.9 0.95 (0.85, 1.07) 0.98 (0.88, 1.10) 0.97 (0.87, 1.09)
Cardiovascular mortality 14 206 6432.7 726 112.9 0.99 (0.83, 1.19) 1.07 (0.89, 1.28) 1.09 (0.91, 1.31)
Cardiovascular composite (stroke, MI
and cardiovascular mortality)
5513 1848.0 297 160.7 1.05 (0.79, 1.39) 1.09 (0.82, 1.46) 1.10 (0.82, 1.48)
Infectious mortality 14 206 6432.7 191 29.7 0.88 (0.61, 1.25) 0.86 (0.61, 1.23) 0.88 (0.61, 1.28)
Infectious hospitalization 5513 1415.1 1792 1266.3 0.96 (0.85, 1.08) 0.96 (0.85, 1.07) 0.96 (0.85, 1.08)
Infectious composite (infectious
hospitalization and infectious morality)
5513 1415.1 1793 1267.0 0.96 (0.85, 1.07) 0.95 (0.85, 1.07) 0.95 (0.85, 1.07)
Patients in IS/FG facilities constitute the reference group. Time-to-event analyses started on the day of reported incidence of ESRD for mortality outcomes and on Day 91 after ESRD for
nonfatal and composite outcomes. *Model 1 adjusted for age, sex, race, Hispanic ethnicity, Medicaid eligibility and incidence year. **Model 2 additionally adjusted for all comorbidities,
bodymass index, serum albumin concentration and estimated glomerular filtration rate. Multiple imputationwas used to address missing data. Results from complete case analyses were not
materially different (not shown).
Table 4. Characteristics of patients initiating dialysis in ferumoxytol and matched IS or sodium FG complex facilities among Medicare Parts A + B patients
Variable (% missing) All patients Ferumoxytol IS or sodium FG complex SD
n or median,
5513
% or IQR n or median ,
1545
% or IQR n or median,
3968
% or IQR
Age (years) 68 57–77 68 57–77 68 57–77 −0.3
Female sex 2478 44.9 709 45.9 1769 44.6 −2.6
Race (<0.1%)
White 3815 69.2 1154 74.7 2661 67.1 5.5
Black 1321 24.0 301 19.5 1020 25.7 −14.6
Asian 307 5.6 77 5.0 230 5.8 −3.3
Other 68 1.2 13 0.8 55 1.4 −4.9
Hispanic ethnicity (0.3%) 861 15.6 292 18.9 569 14.3 12.2
Medicaid eligibility 1855 33.6 496 32.1 1359 34.2 −4.8
Comorbidities
Diabetes 3173 57.6 885 57.3 2288 57.7 −1.2
Hypertension 4857 88.1 1357 87.8 3500 88.2 −2.2
Arteriosclerotic heart disease 1493 27.1 440 28.5 1053 26.5 4.1
Heart failure 2076 37.7 634 41.0 1442 36.3 9.4
Peripheral vascular disease 864 15.7 269 17.4 595 15.0 6.4
Cerebrovascular disease 616 11.2 188 12.2 428 10.8 4.2
Chronic obstructive lung disease 666 12.1 184 11.9 482 12.1 −0.9
Cancer 481 8.7 123 8.0 358 9.0 −3.9
Unable to ambulate 505 9.2 143 9.3 362 9.1 0.3
Unable to transfer 274 5.0 70 4.5 204 5.1 −2.9
Tobacco use 355 6.4 109 7.1 246 6.2 3.3
Drug use 72 1.3 23 1.5 49 1.2 2.1
Alcohol use 87 1.6 29 1.9 58 1.5 3.2
Reported measurements
Body mass index, kg/m2 (1.6%) 27.6 23.6–32.7 27.7 23.5–32.8 27.6 23.7–32.7 −0.02
<18.5 179 3.2 53 3.4 126 3.2 1.4
18.5–24.9 1668 30.3 480 31.1 1188 29.9 2.4
25.0–29.9 1572 28.5 408 26.4 1164 29.3 −6.7
≥30.0 2005 36.4 581 37.6 1424 35.9 3.5
Hemoglobin, g/dL (8.0%) 9.7 8.8–10.7 9.8 8.8–10.7 9.7 8.8–10.7 2.2
Serum albumin, g/dL (21.0%) 3.2 2.7–3.6 3.1 2.7–3.6 3.2 2.7–3.6 −3.0
eGFR at time of dialysis initiation,
mL/min per 1.73 m2 (2.8%)
10.6 7.8–14.1 10.8 7.9–14.6 10.5 7.8–14.0 5.9
Incident hemodialysis patients in the study facilities who had Medicare Parts A and B coverage on Day 90 after initiation of dialysis were captured for analysis of claims-based end points.
eGFR, estimated glomerular filtration rate; IQR, interquartile range; SD, standardized difference.
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However, at least one small trial provides evidence that this class
assumption may not be appropriate and pointed toward a po-
tential increase in infectious risk with IS [12].
A recent Phase II efficacy trial randomized 162 anemic and
iron-deficient patients with CKD, 43% of whom were on dialy-
sis, to 1.02 g of ferumoxytol (2 administrations) or 1 g of IS (5
or 10 administrations) [13]. No difference in the hemoglobin
response after 5 weeks was observed. Rates of serious adverse
events were 9% (ferumoxytol) and 7% (IS), respectively, and
related serious adverse events occurred in 1% in both groups.
Clearly, this study was not powered to detect any differences
in important clinical outcomes such as cardiovascular or infec-
tious events. We are aware of at least three other randomized
head-to-head trials of other agents than ferumoxytol (IS versus
sodium FG complex [14], iron gluconate versus iron saccharate
[15], iron dextran versus IS versus sodiumFG complex [16]). The
former two studies were very small and focused on hemoglobin
as the study end point. The latter study was larger (n = 339) and
focused on safety and found the odds for serious adverse drug
events (all) to be significantly higher with iron dextran compared
with IS.
We are unaware of any observational studies comparing the
safety of ferumoxytol with other iron agents. One single-arm
study of 8666, mostly prevalent, patients who received ferumox-
ytol at three US chains found effectiveness and safety patterns
that were consistent with expectation [6]. Only 126 patients
(1.45%) experienced a total of 375 adverse events, including 45
severe adverse events. Only two (0.02%) patients experienced a
serious anaphylactoid reaction, which is remarkable since the
FDA’s Adverse Event Reporting System (AERS) had registered
unusual activity associatedwith ferumoxytol (serious cardiac dis-
orders) as stated in theAERSQ2/2010 Report [17]. The label was
subsequently amended in November 2010 to include these new
concerns about life-threatening hypersensitivity reactions [18].
However, this study did not draw any informal or formal com-
parison with other cohorts of patients using IS or FG. Therefore,
the findings from our study are informative in that we did not
find any major differences in death and important nonfatal out-
comes in rather similar cohorts of patients cared for in settings
where ferumoxytol versus another intravenous iron formulation
was used for anemia treatment.
Certain limitations of our study require consideration. Our
comparisons of ferumoxytol and IS or FGwere not randomized
and therefore residual confounding remains possible. However,
we used an intuitive quasi-experimental approach that mim-
icked a cluster-randomized trial in which facilities rather than
individual patients are randomized to receiving one treatment
or another. While the current study was not randomized,
treatment with ferumoxytol versus IS or FG was evidently
determined by formulary decisions at the facility level and
independent of patient characteristics. Indeed, after matching
facilities by specific criteria such as location, type and profit
status, patients were similar between ferumoxytol facilities
and those that predominantly used another iron formulation.
Furthermore, we did not conduct a per protocol analysis in
which we would only compare patients based on the drug re-
ceived. For the specific case of intravenous iron injections,
such an approach is impractical since treatment is often not
at regular intervals, especially for ferumoxytol in which higher
doses are given with each injection than with other iron
preparations, and gets initiated dependent on iron status para-
meters and often stopped upon intercurrent (infectious) events.
This per protocol analysis would be prone to time-dependent
confounding which a facility-level analysis can avoid. While we
were able to demonstrate similar anemia practices (mean admi-
nistered iron and erythropoesis-stimulating agent dose, achieved
hemoglobin concentration) between the exposure groups,
we had no information on other iron status parameters
(e.g. ferritin and transferrin saturation). Finally, we were unable
to study the rather rare event of anaphylactoid reactions, for
which our study was vastly underpowered and for which a differ-
ent study design would have been more appropriate.
We conclude that in the typical hemodialysis care setting,
ferumoxytol possess similar short- to mid-term safety profiles
with regard to cardiovascular, infectious andmortality outcomes
compared with the more commonly used intravenous iron for-
mulations IS and FG.
SUPPLEMENTARY DATA
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Impact of extracorporeal blood flow rate on blood pressure, pulse
rate and cardiac output during haemodialysis
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ABSTRACT
Background. If blood pressure (BP) falls during haemodialysis
(HD) [intradialytic hypotension (IDH)] a common clinical
practice is to reduce the extracorporeal blood flow rate
(EBFR). Consequently the efficacy of the HD (Kt/V) is reduced.
However, only very limited knowledge on the effect of reducing
EBFR on BP exists and data are conflicting. The aim of this study
was to evaluate the effect and the potential mechanism(s)
involved by investigating the impact of changes in EBFR on
BP, pulse rate (PR) and cardiac output (CO) in HD patients
with arteriovenous-fistulas (AV-fistulas).
Methods. We performed a randomized, crossover trial in 22
haemodynamically stable HD patients with AV-fistula. After a
conventional HD session each patient was examined during
EBFR of 200, 300 and 400 mL/min in random order. After
15 min when steady state was achieved CO, BP and PR were
measured at each EFBR, respectively.
Results.Mean (SD) agewas 71 (11) years. Systolic BPwas signifi-
cantly higher at an EBFR of 200 mL/min as compared with
300 mL/min [133 (23) versus 128 (24) mmHg; P < 0.05], but
not as compared with 400 mL/min [133 (23) versus 130 (19)
mmHg; P = 0.20]. At EBFRof 200, 300 and 400 mL/min diastolic
BP, mean arterial pressure, PR and CO remained unchanged.
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